DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Ramelteon and Placebo

First Posted Date: 2006-04-21

Last Posted Date: 2010-06-02

Lead Sponsor: Takeda

Target Recruit Count: 25

Registration Number: NCT00316992

Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease

Phase 2

Completed

Conditions: Anemia
Chronic Kidney Disease
Chronic Renal Failure
Pure Red Cell Aplasia

Interventions: Drug: Peginesatide

First Posted Date: 2006-04-17

Last Posted Date: 2019-03-14

Lead Sponsor: Takeda

Target Recruit Count: 22

Registration Number: NCT00314795

Locations: 🇬🇧
Research Facility, London, United Kingdom

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease (GERD)

First Posted Date: 2006-04-11

Last Posted Date: 2012-05-07

Lead Sponsor: Takeda

Target Recruit Count: 2000

Registration Number: NCT00312806

Locations: 🇬🇧
Altana Pharma/Nycomed, Trowbridge, United Kingdom

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Phase 2

Terminated

Conditions: Papillomavirus Infections

Interventions: Drug: 851B

First Posted Date: 2006-04-10

Last Posted Date: 2016-09-23

Lead Sponsor: Takeda

Target Recruit Count: 538

Registration Number: NCT00312286

Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin

First Posted Date: 2006-03-23

Last Posted Date: 2013-03-22

Lead Sponsor: Takeda

Target Recruit Count: 3323

Registration Number: NCT00306384

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Simvastatin
Drug: Lapaquistat acetate and simvastatin

First Posted Date: 2006-02-03

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 1362

Registration Number: NCT00286481

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Insulin
Drug: Alogliptin and insulin

First Posted Date: 2006-02-03

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 390

Registration Number: NCT00286429

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin and glyburide
Drug: Glyburide

First Posted Date: 2006-02-03

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 500

Registration Number: NCT00286468

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Alogliptin

First Posted Date: 2006-02-03

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 329

Registration Number: NCT00286455

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin and metformin
Drug: Metformin

First Posted Date: 2006-02-03

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 527

Registration Number: NCT00286442

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy